Skip to main content
Multiple Sclerosis Discovery Forum
Inspiring Connections
Utility Navigation
Feedback
Newsletter
RSS
Twitter
User Top Menu
Welcome, guest
Log In
Join
Why Join?
Search form
Search
About Us
Overview
Who We Are
Contact
Fan Mail
How to Cite
News & Future Directions
New Findings
News Briefs
Podcasts
News Synthesis
Essays & Opinions
Blogs
Papers
Editors' Picks
Classic Papers
Archive
Forums
Discussions
Webinars
Professional Resources
Meetings & Events
Past Meetings
Funding Opportunities
Jobs
Member Directory
Bulletin Board
Useful Links
Research Resources
Data Visualizations
Clinical Trials - Public Availability of Results
World Map
MS trials baseline
NMO History
NMO Galaxy
Map of MS Prevalence
Progressive MS Authors Galaxy
Word Cloud
MSLine
Ongoing Clinical Trials in MS
MRI-Related Clinical Trials
RRMS and CIS
Immunopathogenesis of MS
The MS Galaxy
ARR in Placebo Groups
Symptoms Prevalence
Scientific Literature TreeMap
Clinical Trials in MS
Drug-Development Pipeline
Tissue Repositories
MSGene
Animal Models
Clinical Trials
Click Here to Support MSDF
You are here
Home
Most Viewed Papers
Suppressive DNA vaccination in myelin oligodendrocyte glycoprotein peptide-induced experimental autoimmune encephalomyelitis involves a T1-biased immune response.
Genetic loci for Epstein-Barr virus nuclear antigen-1 are associated with risk of multiple sclerosis.
Misfiring in multiple sclerosis: Cerebellar Channelopathy, a Potential Novel Target?
Characteristics of demyelinating Charcot-Marie-Tooth disease with concurrent diabetes mellitus.
Characteristics of clinical and electrophysiological pattern of Charcot-Marie-Tooth 4C.
Chronic inflammatory demyelinating polyradiculoneuropathy in solid organ transplant recipients: a prospective study.
Body Esteem Among Women with Multiple Sclerosis and its Relationship with Demographic, Clinical and Socio-Psychological Factors.
Preclinical Models of Multiple Sclerosis: Advantages and Limitations towards Better Therapies.
5-Aminoisoquinolin-1-one (5-AIQ), a Water-Soluble Inhibitor of the Poly¬(ADP Ribose)¬Polymerases (PARPs).
Ethanol-Induced TLR4/NLRP3 Neuroinflammatory Response in Microglial Cells Promotes Leukocyte Infiltration Across the BBB.
Pharmacological Alternatives for the Treatment of Neurodegenerative Disorders: Wasp and Bee Venoms and Their Components as New Neuroactive Tools.
Autoimmune hepatitis/primary biliary cirrhosis overlap syndrome and associated extrahepatic autoimmune diseases.
Palmoplantar Keratoderma and Charcot-Marie-Tooth: combination of two independent genetic diseases? Identification of two point mutations in CMT2 and PPK genes by whole exome sequencing.
Decreased Myelinated Fibers in the Hippocampal Dentate Gyrus of the Tg2576 Mouse Model of Alzheimer's Disease.
Fatigue, depression, and health-related quality of life in patients with multiple sclerosis in Isfahan, Iran.
The natural dual cyclooxygenase and 5-lipoxygenase inhibitor flavocoxid is protective in EAE through effects on Th1/Th17 differentiation and macrophage/microglia activation.
CROP - The Clinico-Radiologico-Ophthalmological Paradox in Multiple Sclerosis: Are Patterns of Retinal and MRI Changes Heterogeneous and Thus Not Predictable?
Human Polyomavirus JC monitoring and noncoding control region analysis in dynamic cohorts of individuals affected by immune-mediated diseases under treatment with biologics: an observational study.
Solar radiation and vitamin d: mitigating environmental factors in autoimmune disease.
Inflammation induces neuro-lymphatic protein expression in multiple sclerosis brain neurovasculature.
Microglia in normal appearing white matter of multiple sclerosis are alerted but immunosuppressed.
MSRV envelope protein is a potent, endogenous and pathogenic agonist of human toll-like receptor 4: Relevance of GNbAC1 in multiple sclerosis treatment.
[Actual medical care situation and therapeutic needs in multiple sclerosis : Impact of the Pharmaceutical Market Restructuring Act (AMNOG)].
Crosstalk between endocannabinoid and immune systems: a potential dysregulation in depression?
New pharmacological approaches against chronic bowel and bladder problems in paralytics.
Pages
« first
‹ previous
…
665
666
667
668
669
670
671
672
673
…
next ›
last »